International Conference on Cancer Science and Research

Advancing Cancer Care: Stem Cell Therapy for Radiotherapy Complications

Featured Speaker: Dr. Alain Chapel, Institute of Radiological Protection and Nuclear Safety, France

Session Type: Oral Virtual Presentation

Topic: From experimental research to clinical trial in the treatment of complication of radiotherapy by stem cells

🌟 Why This Research Matters

Radiotherapy remains a cornerstone in cancer treatment, but nearly 5–10% of patients develop serious long-term side effects, especially after pelvic radiation. These complications often lack standardized treatment, making innovation in this area a pressing need. Dr. Alain Chapel and his team have been exploring mesenchymal stromal stem cell (MSC) therapy as a potential breakthrough solution.

🔍 Key Insights from the Study

· Clinical Problem: Late adverse gastrointestinal and pelvic complications post-radiotherapy can be life-threatening.

· Preclinical Evidence: Animal models demonstrated that systemic MSC injections significantly alleviated radiation-induced damage.

· Phase I Clinical Trial Results:

o Patients experienced reduction in diarrhea, pain, hemorrhage, and inflammation.

o Fistulization process was halted in one patient with remission lasting over 3 years.

o No toxicity observed, supporting a favorable safety profile.

· Ongoing PRISME Trial (NCT02814864):

o Involves 12 patients across 6 radiotherapy centers.

o Each patient receives three MSC injections at weekly intervals.

o Primary goal: measurable improvement on LENT SOMA scale for rectal bleeding or hematuria.

o Secondary goals: reduced need for pain medication, fewer digestive issues, and better quality of life.

· Future Outlook: A Phase III clinical trial is planned if current results confirm long-term efficacy.

👨‍🔬 About Dr. Alain Chapel

Dr. Alain Chapel, PhD, has dedicated more than 30 years to advancing cell and gene therapy for radiation-induced damage. His work bridges experimental models with real-world clinical applications. He has collaborated on groundbreaking compassionate trials demonstrating MSC therapy’s effectiveness in hematopoietic failure, radiodermatitis, and radiotherapy overdoses. His extensive contributions also include editorial roles in leading international journals and active participation in global research societies.

📢 Join the Conference

Be part of this global platform where cutting-edge cancer research meets clinical innovation.

Event: International Conference on Cancer Science and Research

📍 Venue: Village Hotel Changi, Singapore
📅 Dates: November 17–19, 2025
🌐 Website: cancer.miconferences.com
✉️ Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448 | WhatsApp: +1 (424) 377 0967

👉 Register Now | Submit Abstract

#CancerScience2025 #StemCellResearch #RadiotherapyComplications #CancerTreatment #OncologyConference #MSCtherapy #CancerInnovation #CancerResearch

Endothelial RhoA: Unlocking a New Frontier in Anti-Metastatic Cancer Therapy

📅 Event Dates: November 17–19, 2025

📍 Venue: Village Hotel Changi, Singapore | 🌐 Hybrid (In-Person & Virtual)
🎤 Speaker: Dr. Constantinos M. Mikelis, University of Patras, Greece

Title : The regulatory role of endothelial RhoA on tumor microenvironment

🔬 Presentation Highlights

· The endothelial barrier actively regulates tumor growth, dissemination, and metastasis.

· Transendothelial migration of tumor cells is a key step in metastasis.

· Research findings show that endothelial RhoA activation plays a decisive role in this process.

· Breast tumor cells trigger endothelial RhoA via paracrine signaling and cell-to-cell contact.

· Blocking RhoA genetically or pharmacologically reduces tumor cell migration and metastasis in human and murine tumor models.

· These results identify endothelial RhoA as a universal therapeutic target for anti-metastatic treatment of solid tumors.

👨‍🔬 About Dr. Constantinos M. Mikelis

· Associate Professor of Physiology at the University of Patras, Greece.

· Adjunct Associate Professor at Texas Tech University Health Sciences Center, USA.

· PhD focused on angiogenesis, University of Patras.

· Postdoctoral training at NIH, USA in vascular and cancer biology.

· Research expertise: Small GTPases, GPCRs, angiogenesis, endothelial biology, and tumor microenvironment.

📢 About the Event – International Conference on Cancer Science and Research 2025

This global event will gather leading oncologists, researchers, clinicians, and industry experts to share cutting-edge advancements in cancer biology, therapy, and clinical research.

· 🌍 Hybrid Mode: Attend in Singapore or join virtually.

· 📄 Abstract Submission: Click Here

· 📝 Registration: Click Here

· 🔗 Event Website

📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
📲 WhatsApp: +1 (424) 377 0967

🔗 Social: Facebook | X (Twitter)

#CancerScience2025 #InternationalCancerConference #CancerResearch #TumorMicroenvironment #EndothelialRhoA #OncologyConference #SingaporeConference

Copper(II) Complexes: A New Horizon in Cancer Chemotherapy

Featuring Dr. Salah S. Massoud – University of Louisiana, United States

📍 Oral In-Person Presentation at the International Conference on Cancer Science andResearch
📅 November 17–19, 2025 | Village Hotel Changi, Singapore

Title: Copper(II) complexes as potent chemotherapeutic agents for anticancer therapy

Why Copper(II) Complexes?

Cancer continues to be one of the most critical health challenges of our time. According to the World Health Organization (WHO), cancer claimed nearly 10 million lives in 2022, and projections suggest this number may rise to 16.4 million by 2040. While platinum-based drugs such as cisplatin, carboplatin, and oxaliplatin revolutionized chemotherapy, their severe side effects—including nephrotoxicity, neurotoxicity, immune suppression, and drug resistance—have limited their long-term effectiveness.

In this context, Copper(II) complexes are emerging as powerful candidates for next-generation chemotherapy. Over the past two decades, research has revealed their high cytotoxicity, better pharmacological profiles, and selective action against cancer cells. Notably, binuclear pyridyl-phenoxido Cu(II) complexes demonstrated remarkable antiproliferative activity with a high selectivity index in ovarian (A2780) and breast cancer (MCF-7) cell lines. Dr. Massoud’s presentation will highlight how these complexes function, their mechanisms of action, and their potential to transform cancer therapy.

About the Speaker

Dr. Salah S. Massoud is a renowned Distinguished Professor at the University of Louisiana, USA, and Alexandria University, Egypt. He earned his Ph.D. in Bioinorganic and Inorganic Chemistry from Boston University, following his B.Sc. and M.Sc. from Alexandria University.

His scientific journey is remarkable—200+ peer-reviewed publications, 200+ invited lectures worldwide, and groundbreaking research contributions in copper-based anticancer drugs, DNA cleavage, ATP hydrolysis, molecular magnetism, and lanthanide fluorescence. Beyond his research, Dr. Massoud actively serves on editorial boards and as a guest editor for leading scientific journals, influencing the global scientific community.

Conference Information

Event: International Conference on Cancer Science and Research

📅 Dates: November 17–19, 2025

📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502

📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967

🔗 Stay connected: Facebook | X (Twitter)

🔗 Click here to Register | Submit Your Abstract

#CancerResearch #OncologyConference #CancerScience2025 #CopperComplexes #CancerTherapy #ChemotherapyResearch #OncologyInnovation #MedicalResearch

Cardiac Coherence: A New Approach to Oncology Medicine

We are delighted to feature Nabhan Linda, Clinical Psychologist from France Digital University, France, who will be delivering a Poster Virtual Presentation at the International Conference on Cancer Scienceand Research, scheduled for November 17–19, 2025, at the Village Hotel Changi, Singapore.

Abstract

In the oncology clinic, the issue of anguish, stress and anxiety is a very important part of treatment. These affects can also condition the outcome of treatment, as well as patients' experiences of their disease. Cancer has specific psychological repercussions compared with other illnesses that do not call so deeply on the subject's being. How can we deal with anxiety other than by taking medication? From patients who have never used anxiolytics or antidepressants to those who are wary of them, the powerlessness in the face of such intimate and intrinsic suffering is being felt. Indeed, anxiety is at the heart of the patient's history. Not everyone experiences anxiety in the same way, or for the same reasons. On the one hand, it is a question of identifying these types of feelings and then trying to understand the ins and outs of them. There's something quite special about psychological suffering: it can't be understood. In other words, there is an inability to share feelings with others that plunges the subject into this distress. Welcoming people with words is our first line of approach to this suffering, but how can we really act? This is where the relevance of cardiac coherence comes in.

Cardiac coherence is a method of refocusing the subject which has a dual effect on the nervous system by activating breathing, and which in turn has an impact on the psyche.

What was interesting to observe was that, in reality, once in a state of anxiety, the emergency having been declared, it is extremely difficult to act on these moments when the patient is in a state of total feeling and is only trying not to drown in his thoughts and feelings. Introducing cardiac coherence into the world of oncology makes it possible to provide a method of preparing for the onset of anxiety. It is very complicated to anticipate anxiety and sometimes impossible to detect its triggers, but training your mind and spirit to react to the micro-signs that herald an emotional catastrophe is essential, all the more so in oncology medicine where the body is bruised.

What we have observed is linked to the person's basic level of stress. Is there a mental invasion, a cognitive disorder or even a difficulty in concentrating on myself that prevents access to the full potential of this method? As well as praising this technique, which has proved its worth, it sometimes gives an indication of a person's emotional and psychic interiority. It is by working in combination with psychotherapy that real, effective care can be provided in an oncology medicine that aims to be closer to humanity.

Biography

Nabhan Linda is a clinical psychologist specialising in oncology. She has worked with a large number of psychiatric patients in hospital, then oncology patients in adult wards, before developing her private practice. A cardiac coherence practitioner and founder of the OncopsyHeart Mindcare collective, she continues to develop her practice and her knowledge through numerous articles on oncology medicine.

📅 Event Dates: November 17–19, 2025
📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502
🌐 Event Website: https://cancer.miconferences.com/
📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
📱 WhatsApp: +1 (424) 377 0967

🔗 Follow us for updates:

Facebook: Mathews Events
X (Twitter): Cancer World Conference

# Cardiaccoherence #Oncology #anxiety #NervousSystem #psychotherapy #Cancer2025 #MedicalOncologyConferences #UpcomingOncologyConferences #CancerResearch

GPER-driven Crosstalk in Breast Cancer: Bridging Drug Resistance and Tumor Microenvironment Remodelling

We are honored to announce that Dr. Tenghua Yu, Associate Chief Physician and Deputy Director of the Breast Surgery Department at Jiangxi Cancer Hospital & Institute, China, will be delivering an Oral Virtual Presentation at the International Conference on Cancer Science and Research, scheduled for November 17–19, 2025, at Village Hotel Changi, Singapore.

Presentation Overview

Triple-negative breast cancer (TNBC) remains one of the most aggressive and challenging forms of breast cancer, marked by poor prognosis and limited treatment options. Dr. Yu’s research sheds new light on the role of G protein-coupled estrogen receptor (GPER) in regulating the tumor microenvironment, particularly its interaction with cancer-associated fibroblasts (CAFs).

His study reveals how estrogen-activated GPER in CAFs stimulates glutamine production through the upregulation of key metabolic enzymes (GLUL and LDHB). This glutamine is then secreted and absorbed by TNBC cells, fueling their growth, motility, and resistance to chemotherapy. By elucidating the GPER/cAMP/PKA/CREB signaling pathway and its impact on metabolic coupling, Dr. Yu identifies GPER as a critical mediator of tumor progression.

The findings emphasize that targeting the estrogen/GPER/glutamine axis could offer promising therapeutic strategies to overcome resistance and suppress TNBC progression. This work highlights the growing importance of metabolic interventions in cancer treatment.

About Dr. Tenghua Yu

Dr. Yu is a dedicated clinician and researcher specializing in breast cancer treatment and tumor microenvironment studies. He earned his PhD from Chongqing Medical University (2013–2016) and furthered his research training at the University of Chicago Medical Center, USA (2024–2025). With more than 30 peer-reviewed publications in esteemed journals such as Oncogene, Clinical and Translational Medicine, and Molecular Cell Endocrinology, Dr. Yu continues to make significant contributions to the field of oncology.

Conference Details

📅 Dates: November 17–19, 2025
📍 Venue: Village Hotel Changi, 1 Netheravon Rd, Singapore 508502
🌐 Website: https://cancer.miconferences.com/
📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967

#CancerConferences #Oncogene #TraditionalMedicine #CancerResearch #Oncology #Chemotherapy #Cancer2025 #OncologyConferences #GPER #TNBCcells

Extracellular vesicle pathways as regulators of tumor-vascular interactions in glioblastoma

🧠 Virtual Presentation Spotlight – Cancer Conference 2025

📅 November 17–19, 2025 | 📍 Village Hotel Changi, Singapore & Online
🌐 Event Website

We are delighted to welcome Prof. Janusz Rak, MD, PhD, McGill University, Canada, as a distinguished Oral Virtual Presenter at the Cancer Conference 2025. Prof. Rak is a world-leading expert in pediatric hematology/oncology, renowned for his pioneering research into how cancer cells communicate with their environment via extracellular vesicles (EVs).

Presentation Title:
Extracellular vesicle pathways as regulators of tumor-vascular interactionsin glioblastoma

Glioblastoma (GBM) remains one of the most aggressive and lethal brain tumors, resisting conventional therapies despite decades of study. Prof. Rak’s groundbreaking work sheds new light on the critical role of extracellular vesicles in orchestrating communication between glioma stem cells (GSCs) and the vascular system—driving processes like angiogenesis, vasectasia, and immune cell access to tumor tissue.

His team has uncovered that GSC subtypes secrete unique repertoires of EVs, influencing vascular growth patterns in GBM. Of particular interest is their discovery of a VEGF-independent blood vessel enlargement process—vasectasia—triggered by EV-mediated transfer of oncogenic EGFRvIII to endothelial cells, which resists standard angiogenesis inhibitors. Moreover, endothelial-derived EVs can reprogram proneural GSCs into more invasive, therapy-resistant mesenchymal phenotypes. These insights reveal new therapeutic possibilities, including combining vascular modulation with immunotherapy to improve treatment outcomes.

About the Speaker:
Prof. Janusz Rak is a Professor of Pediatrics and Jack Cole Chair in Pediatric Hematology/Oncology at McGill University. He directs the Centre for Applied Nanomedicine (CAN) and leads innovative projects on EV-based liquid biopsy approaches in pediatric cancer. He is also a Fellow of the Royal Society of Canada, recognized for his exceptional contributions to cancer biology.

📞 Contact Us
📧 Email: cancer@mathewsconference.com
📱 WhatsApp: +1 (424) 377 0967
📞 Phone: +1 (312) 462-4448

#Glioblastoma #BrainCancerResearch #CancerConference #LiquidBiopsy #OncologyResearch #VirtualConference #MedicalResearch #Cancer2025

Pages